A detailed history of Rhumbline Advisers transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 99,653 shares of SWTX stock, worth $3.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99,653
Previous 104,656 4.78%
Holding current value
$3.73 Million
Previous $3.94 Million 19.03%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$32.04 - $42.76 $160,296 - $213,928
-5,003 Reduced 4.78%
99,653 $3.19 Million
Q2 2024

Aug 01, 2024

BUY
$36.06 - $47.62 $183,220 - $241,957
5,081 Added 5.1%
104,656 $3.94 Million
Q1 2024

May 09, 2024

BUY
$36.5 - $52.5 $164,651 - $236,827
4,511 Added 4.75%
99,575 $4.9 Million
Q4 2023

Feb 08, 2024

BUY
$18.94 - $37.24 $164,247 - $322,945
8,672 Added 10.04%
95,064 $3.47 Million
Q3 2023

Nov 09, 2023

BUY
$23.12 - $31.38 $146,696 - $199,106
6,345 Added 7.93%
86,392 $2 Million
Q2 2023

Aug 08, 2023

BUY
$23.15 - $32.71 $510,596 - $721,451
22,056 Added 38.03%
80,047 $2.1 Million
Q1 2023

May 11, 2023

SELL
$24.97 - $34.05 $1,548 - $2,111
-62 Reduced 0.11%
57,991 $1.49 Million
Q4 2022

Feb 14, 2023

BUY
$21.73 - $28.72 $107,324 - $141,848
4,939 Added 9.3%
58,053 $1.51 Million
Q3 2022

Nov 10, 2022

BUY
$24.1 - $39.66 $114,547 - $188,503
4,753 Added 9.83%
53,114 $1.52 Million
Q2 2022

Aug 11, 2022

BUY
$18.36 - $60.07 $325,559 - $1.07 Million
17,732 Added 57.89%
48,361 $1.19 Million
Q1 2022

May 12, 2022

BUY
$48.97 - $65.46 $53,915 - $72,071
1,101 Added 3.73%
30,629 $1.73 Million
Q4 2021

Feb 10, 2022

BUY
$53.3 - $75.84 $7,462 - $10,617
140 Added 0.48%
29,528 $1.83 Million
Q3 2021

Nov 12, 2021

BUY
$62.66 - $88.26 $58,148 - $81,905
928 Added 3.26%
29,388 $1.86 Million
Q2 2021

Aug 05, 2021

BUY
$67.45 - $85.63 $161,745 - $205,340
2,398 Added 9.2%
28,460 $2.35 Million
Q1 2021

May 06, 2021

SELL
$65.1 - $93.59 $115,552 - $166,122
-1,775 Reduced 6.38%
26,062 $1.92 Million
Q4 2020

Feb 10, 2021

BUY
$48.36 - $77.92 $175,595 - $282,927
3,631 Added 15.0%
27,837 $2.02 Million
Q3 2020

Nov 12, 2020

SELL
$36.14 - $51.99 $124,249 - $178,741
-3,438 Reduced 12.44%
24,206 $1.15 Million
Q2 2020

Aug 13, 2020

BUY
$22.98 - $48.57 $353,708 - $747,589
15,392 Added 125.63%
27,644 $1.16 Million
Q1 2020

May 06, 2020

BUY
$20.44 - $41.21 $57,763 - $116,459
2,826 Added 29.98%
12,252 $331,000
Q4 2019

Feb 05, 2020

BUY
$17.74 - $39.52 $167,217 - $372,515
9,426 New
9,426 $363,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.34B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.